Wave Life Sciences/$WVE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Wave Life Sciences
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Ticker
$WVE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Singapore, Singapore
Employees
288
ISIN
SG9999014716
Website
WVE Metrics
BasicAdvanced
$1.1B
-
-$0.77
-0.92
-
Price and volume
Market cap
$1.1B
Beta
-0.92
52-week high
$15.84
52-week low
$4.25
Average daily volume
1.1M
Financial strength
Current ratio
2.953
Quick ratio
2.782
Long term debt to equity
8.746
Total debt to equity
13.134
Profitability
EBITDA (TTM)
-122.02
Gross margin (TTM)
-59.00%
Net profit margin (TTM)
-107.04%
Operating margin (TTM)
-119.83%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-30.02%
Return on equity (TTM)
-105.50%
Valuation
Price to revenue (TTM)
9.639
Price to book
6.19
Price to tangible book (TTM)
6.19
Price to free cash flow (TTM)
-5.578
Free cash flow yield (TTM)
-17.93%
Free cash flow per share (TTM)
-123.69%
Growth
Revenue change (TTM)
-7.06%
Earnings per share change (TTM)
40.29%
3-year revenue growth (CAGR)
34.93%
10-year revenue growth (CAGR)
129.40%
3-year earnings per share growth (CAGR)
-29.12%
10-year earnings per share growth (CAGR)
-6.49%
What the Analysts think about WVE
Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.
Bulls say / Bears say
Wave Life Sciences reported a net income of $29.3 million for Q4 2024, a significant turnaround from a net loss of $16.3 million in the same quarter of the previous year, indicating improved financial performance. (Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update)
The company announced positive data from the FORWARD-53 clinical trial in Duchenne Muscular Dystrophy, showing significant functional benefits and reversal of muscle damage after 48 weeks of dosing with WVE-N531, which could enhance its market position in rare disease treatments. (Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531)
Wave Life Sciences initiated the Phase 1 INLIGHT clinical trial of WVE-007 targeting obesity, expanding its pipeline into prevalent conditions and potentially tapping into a large market. (Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity)
Despite the positive Q4 2024 results, Wave Life Sciences reported a net loss of $46.9 million for Q1 2025, indicating ongoing financial volatility. (Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update)
The company's revenue for Q1 2025 was $9.2 million, a decrease from $12.5 million in the same quarter of the previous year, suggesting potential challenges in revenue growth. (Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update)
Wave Life Sciences' cash and cash equivalents decreased from $302.1 million as of December 31, 2024, to $243.1 million as of March 31, 2025, which may raise concerns about cash burn rates and financial sustainability. (Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
WVE Financial Performance
Revenues and expenses
WVE Earnings Performance
Company profitability
WVE News
AllArticlesVideos
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·1 month ago
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Wave Life Sciences stock?
Wave Life Sciences (WVE) has a market cap of $1.1B as of June 20, 2025.
What is the P/E ratio for Wave Life Sciences stock?
The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of June 20, 2025.
Does Wave Life Sciences stock pay dividends?
No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Wave Life Sciences dividend payment date?
Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.
What is the beta indicator for Wave Life Sciences?
Wave Life Sciences (WVE) has a beta rating of -0.92. This means that it has an inverse relation to market volatility.